近期轴性脊柱关节炎中银屑病的患病率及其后果:DESIR队列6年分析
基于多中心前瞻性DESIR队列(NCT01648907)589例近期炎性背痛提示axSpA的成人患者,随访6年。银屑病累积患病率从基线16.8%(99/589)升至6年26.8%(158/589),发病率为2.1/100患者年。合并银屑病者6年内滑膜炎更多、甲氨蝶呤和生物制剂使用更多,但疾病活动度、功能和生活质量无显著差异。
要点
- 近期axSpA患者银屑病累积患病率从基线16.8%升至6年26.8%,发病率2.1/100患者年。
- 合并银屑病者6年内滑膜炎更多(p=0.008),甲氨蝶呤累积使用25.5% vs 11.8%(p<0.001)。
- 合并银屑病者生物制剂累积使用55.7% vs 38.5%(p<0.001),但ASDAS-CRP、HAQ-AS和生活质量无显著差异。
核心结论
- 银屑病在早期axSpA中常见,合并银屑病者随时间出现更多肿胀关节并接受更多生物制剂,但axSpA活动度和严重度相关结局未更差。
研究设计与样本
- 多中心前瞻性队列DESIR(NCT01648907),纳入589例近期炎性背痛提示axSpA的成人患者,随访6年。
- 每次访视记录银屑病,计算累积患病率和发病率,比较任一时间点有 vs 无银屑病患者。
- 结局包括疾病活动度(ASDAS-CRP、关节和附着点计数、CRP)、患者报告结局(HAQ-AS功能、生活质量)及6年治疗使用,采用单变量和多变量分析及线性混合效应模型比较。
主要发现
- 589例患者平均年龄40.5±8.7岁,45.8%为男性,基线平均症状持续时间1.5±0.9年。
- 银屑病累积患病率从基线16.8%(99/589)增至6年26.8%(158/589),发病率为2.1/100患者年。
- 6年随访中,合并银屑病者出现更多滑膜炎(p=0.008)。
- 合并银屑病者甲氨蝶呤累积使用25.5% vs 11.8%(p<0.001),生物制剂累积使用55.7% vs 38.5%(p<0.001)。
- 银屑病对其他结局无显著影响,包括疾病活动度(ASDAS-CRP)、功能(HAQ-AS)和生活质量。
关键数值与推荐
- 银屑病累积患病率:基线16.8%(99/589),6年26.8%(158/589),发病率2.1/100患者年。
- 滑膜炎比较:有银屑病 vs 无银屑病 p=0.008。
- 甲氨蝶呤累积使用:有银屑病25.5% vs 无银屑病11.8%,p<0.001。
- 生物制剂累积使用:有银屑病55.7% vs 无银屑病38.5%,p<0.001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The consequences of psoriasis associated to axial spondyloarthritis (axSpA) are unclear. The objectives were to determine the prevalence and the consequences of psoriasis in recent axSpA over 6 years of follow-up. METHODS: The multicentric prospective cohort DESIR (NCT01648907) of adult patients with recent inflammatory back pain suggestive of axSpA was analysed over 6 years. Psoriasis was recorded at each visit and cumulative prevalence and incidence were calculated. Patients with vs without psoriasis at any time point were compared. Outcomes included disease activity (Ankylosing Spondylitis Disease Activity Score-C reactive protein (ASDAS-CRP), joint and enthesitis count, CRP), patient-reported outcomes for function (Health Assessment Questionnaire for axSpA, HAQ-AS) and quality of life, and treatment use over 6 years. Outcomes were compared through univariable and multivariable analyses, as well as linear mixed effect models. RESULTS: In 589 patients, mean age 40.5±8.7 years, 45.8% men and baseline mean symptom duration 1.5±0.9 years, the cumulative prevalence of psoriasis increased from 16.8% (99/589) at baseline to 26.8% (158/589) at 6 years, leading to an incidence of 2.1/100 patient-years. Over 6 years of follow-up, patients with psoriasis developed more synovitis (p=0.008), and received more methotrexate (cumulative use, 25.5% vs 11.8%, p<0.001) and biological disease-modifying drugs (55.7% vs 38.5%, p<0.001). There were no significant consequences of psoriasis on other outcomes, including disease activity (ASDAS-CRP), functional capacity (HAQ-AS) and quality of life. CONCLUSION: Psoriasis is frequent in early axSpA. AxSpA patients with psoriasis had more swollen joints over time and received more biologics; they did not have worse outcomes related to axSpA in terms of activity and severity. TRIAL REGISTRATION NUMBER: NCT01648907.
引用
- Lucasson F, Richette P, Aouad K, et al. Prevalence and consequences of psoriasis in recent axial spondyloarthritis: an analysis of the DESIR cohort over 6 years. RMD Open. 2022. PMID: 35091462. doi:10.1136/rmdopen-2021-001986
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。